Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)–European Society of Gynaecologic Oncology (ESGO)–Gynecologic Cancer InterGroup (GCIG)–International Society for the Study of Trophoblastic Diseases (ISSTD)
Authors:
- Christianne LokCLChristianne Lok
- Nienke van TrommelNTNienke van Trommel
- Elena Ioana BraicuEBElena Ioana Braicu
- Michael SecklMSMichael Seckl
- EOTTD-ESGO-GCIG-ISSTD Guideline CommitteeECEOTTD-ESGO-GCIG-ISSTD Guideline Committee
Top Cited Papers
- 20 June 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (18) , 2119-2128
Abstract
Gestational trophoblastic diseases (GTDs) are a group of pregnancy-related premalignant and malignant diseases with generally a favorable prognosis when treated adequately. Many different treatment protocols exist worldwide. To our knowledge, this is the first set of global consensus-based guidelines for GTD. Four international organizations (European Organisation for the Treatment of Trophoblastic Diseases, European Society of Gynecologic Oncology, Gynecologic Cancer Intergroup, and International Society for the Study of Trophoblastic Diseases) delegated 53 expert GTD clinicians from 31 countries who formulated nine consensus-based definitions and the minimum criteria required to be a GTD center. Furthermore, 18 flow diagrams were developed to diagnose, treat, and follow up all forms of primary or recurrent GTD. The definitions and flow diagrams were drafted and adapted in consecutive (online) meetings until consensus was reached followed by an external review process. Here, the final guidelines are presented together with the available supporting evidence from the literature.Keywords
This publication has 59 references indexed in Scilit:
- Perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia: a systematic review of observational studies and meta-analysisAmerican Journal of Obstetrics and Gynecology, 2022
- Pathology of gestational trophoblastic disease (GTD)Best Practice & Research Clinical Obstetrics & Gynaecology, 2021
- Genetics of gestational trophoblastic diseaseBest Practice & Research Clinical Obstetrics & Gynaecology, 2021
- Clinical presentation and diagnosis of Gestational Trophoblastic DiseaseBest Practice & Research Clinical Obstetrics & Gynaecology, 2021
- Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapyESMO Open, 2021
- Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic diseaseEuropean Journal of Cancer, 2020
- The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasiaEuropean Journal of Cancer, 2019
- Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate aloneAmerican Journal of Obstetrics and Gynecology, 2016
- Phase II trial of pulse dactinomycin as salvage therapy for failed low‐risk gestational trophoblastic neoplasiaCancer, 2006
- Single-dose actinomycin-D treatment for nonmetastatic gestational trophoblastic disease: A prospective phase II trial of the gynecologic oncology groupCancer, 1987